Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study

Long-acting bronchodilators including muscarinic antagonists are central to the management of patients with COPD. The Glycopyrrolate Effect on syMptoms and lung function (GEM2) study assessed the efficacy and safety of twice-daily glycopyrrolate 15.6 μg in patients with moderate-to-severe airflow li...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Chronic Obstr Pulm Dis
Autors principals: Kerwin, Edward, Siler, Thomas M., Korenblat, Phillip, White, Alexander, Eckert, Joerg H., Henley, Michelle, Patalano, Francesco, D’Andrea, Peter
Format: Artigo
Idioma:Inglês
Publicat: COPD Foundation Inc 2016
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5559157/
https://ncbi.nlm.nih.gov/pubmed/28848879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15326/jcopdf.3.2.2015.0157
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars